CEBPZ and acute myeloid leukemia: Khan et al. interestingly showed that the CD34+CD38- fraction of adult patients with CBF-AML expressed CD33, while patients with intermediate- and adverse-risk disease displayed a more heterogeneous CD34+CD38- fraction, containing significant numbers of CD33-negative cells [18].